EWTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edgewise Therapeutics Inc (EWTX) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The company's strong pipeline, positive analyst sentiment, and upcoming catalysts make it a compelling choice despite minor technical and financial concerns.
The technical indicators show mixed signals. The MACD is negative but contracting, RSI is neutral at 54.387, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading above its pivot point of 29.409, with resistance at 31.298 and support at 27.519.
Analysts have raised price targets significantly, with JPMorgan and Evercore ISI setting targets at $45, indicating strong growth potential.
Edgewise's EDG-7500 drug shows promise in treating hypertrophic cardiomyopathy, with upcoming data in Q2 2026 expected to be meaningful.
Recent data on the muscular dystrophy treatment sevasemten has bolstered confidence in the company's pipeline.
Concerns about safety signals in EDG-7500 trials, including atrial fibrillation, may impact investor sentiment until Phase 3 data is available.
Financials show a net loss of $50.2M in Q4 2025, though losses have narrowed YoY.
In Q4 2025, the company reported no revenue growth (0.00% YoY) and a net loss of $50.2M, which improved by 26.61% YoY. EPS improved by 11.90% YoY to -0.47, but the company remains unprofitable.
Analysts are overwhelmingly positive, with multiple firms raising price targets and maintaining Buy or Overweight ratings. JPMorgan added Edgewise to its Analyst Focus List as a growth idea, citing confidence in its pipeline and upcoming catalysts.
